Organizing co mmittee

Executive Committee 
 
Abdurakhmanov J.M. 
Abdurakhmonov B. A. 
Bobakulov Kh.M. 
Ibotov Sh.Kh 
Ismailova D.S. 
Kalbaeva G.K. 
Khalilova E. Kh. 
Khasanov Sh.Sh. 
Kodiralieva F.A. 
Kodirova D.R. 
Mamatkhanova M.A. 
Mezhlumyan L.G. 
Mukhamatkhanova R.F. 
Sanoev Z.I. 
Usmanov D.A. 
Acad. S.Yu.Yunusov Institute of the Chemistry of Plant Substances, 
77, Mirzo-Ulugbek Str., Tashkent, 100170, Uzbekistan

---

 
 
 
 
 
 
 
 
 
 
 
 
PLENARY
PRESENTATION 
 
 
 

---

Plenary presentation
1 
TARGETED AGENTS FOR CANCER DIAGNOSTICS AND 
THERAPY 
Sergey Deyev
Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, 
Russian Academy of Sciences, Moscow, Russia 
Oncoteranostics (therapy + diagnostics) is a discipline that combines the diagnosis of 
a malignant neoplasm and personalized treatment of a patient, represents a promising 
medical strategy. It is based on accurate diagnostics of molecular targets of pathogenic 
cells and targeted exposure to them to ensure high selectivity of antitumor therapy. The 
teranostics approach is currently one of the most dynamically developing areas in the 
cancer treatment. The latest advances in the fields of genetic engineering and 
nanobiotechnology allow us to realize the concept of creating multifunctional structures 
that combine the functions of detection and therapy of pathology lesions, and it also 
becomes possible to monitor treatment. 
Our recent results [1-14] on design of targeted agent
s 
with important types of 
anticancer compounds including radionuclide, photosensitizers, biological toxic 
principles as well as of nano-vehicle (liposomes, MOF, PLGA nanoparticles, 
luminescent UCNP upconversion nanoparticles) will be reviewed. The obtained results 
show promise for effective combined oncotherapy leading to prospective translation to 
clinical practices. 
1.
Bragina O., et al. (2022). Phase I trial of 99mTc-(HE) 3-G3, a DARPin-based probe for 
imaging of HER2 expression in breast cancer. 
Journal of Nuclear Medicine
, 
63
(4), 528-535. 
2.
Zelepukin I.V., 
et al.
(2022). Flash drug release from nanoparticles accumulated in the 
targeted blood vessels facilitates the tumour treatment. 
Nat Commun
. 
13
(1), 6910. 
3.
Stepanov A.V., 
et al. 
Switchable targeting of solid tumors by BsCAR T cells. 
Proc Natl 
Acad Sci USA
. (2022). 
119
(46), e2210562119. 
4.
Abakumova T.O., et al. (2022). Barnase-Loaded Vaterite Nanoparticles Functionalized 
by EpCAM Targeting Vectors for the Treatment of Lung Diseases. 
ACS Applied Nano 
Materials
, 
5
(8), 10744-10754. 
5.
Xu T., et al. (2022). Epithelial cell adhesion molecule-targeting designed ankyrin repeat 
protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer 
cells. 
Oncology Reports
, 
47
(5), 1-10. 
6.
Tolmachev V.M., 
et al.
(2022). Targeted nuclear medicine. Seek and destroy. 
Russian 
Chemical Reviews
, 
91
(3), RCR5034.
7.
Shramova E.I., et al. (2022). Genetically encoded BRET-activated photodynamic 
therapy for the treatment of deep-seated tumors. 
Light: Science & Applications
, 
11
(1), 1-13. 
8.
Zelepukin I.V., et al. (2022). Direct photoacoustic measurement of silicon nanoparticle 
degradation promoted by a polymer coating. 
Chemical Engineering J.
, 
430
, 132860. 
9.
Kalinovsky D.V., et al. (2022). Therapeutic efficacy of antibody-drug conjugates 
targeting GD2-positive tumors. 
Journal for immunotherapy of cancer
, 
10
(6). 
10.
Shipunova V.O., et al. (2021). Targeting Cancer Cell Tight Junctions Enhances PLGA-
Based Photothermal Sensitizers’ Performance In Vitro and In Vivo. 
Pharmaceutics
, 
14
(1), 43. 
11.
Shramova E.I., et al. (2021). Barnase*Barstar-guided two-step targeting approach for 
drug delivery to tumor cells in vivo. 
J. Controlled Release
, 
340,
200-208. 
12.
Shilova O., et al. (2021). Barnase-Barstar Pair: Contemporary Application in Cancer 
Research and Nanotechnology. 
Molecules
, 
26
(22), 6785. 
13.
Ukrainskaya V., et al. (2021). Antigen‐Specific Stimulation and Expansion of CAR‐T 
Cells Using Membrane Vesicles as Target Cell Surrogates. 
Small
, 
17
(45), 2102643. 

---

Plenary presentation 
2